Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options

Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour

(2013) Zeinab Elsawaf et al.   BREAST

Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation

(2013) Keely M. McNamara et al.   CANCER SCIENCE

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases

(2013) Ernst Schonbrunn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer

(2013) Luciano Cascione et al.   PLoS One

Decreased Androgen Receptor Expression Is Associated With Distant Metastases in Patients With Androgen Receptor–Expressing Triple-Negative Breast Carcinoma

(2012) Lisa M. Sutton et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events

(2012) Kate M Peters et al.   BMC CANCER

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network

(2012) Nancy U. Lin et al.   CANCER

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome

(2012) Emilia Montagna et al.   Clinical Breast Cancer

Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6

(2012) L. H. Tang et al.   CLINICAL CANCER RESEARCH

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Androgen receptor in triple negative breast cancer

(2012) K.M. McNamara et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

(2012) T. E. Hickey et al.   MOLECULAR ENDOCRINOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers

(2011) S. Park et al.   ANNALS OF ONCOLOGY

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer

(2011) Min Ni et al.   CANCER CELL

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer

(2011) Dabei Tang et al.   MEDICAL ONCOLOGY

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray

(2011) Jiehua He et al.   MEDICAL ONCOLOGY

Triple-Negative Breast Cancer: An Unmet Medical Need

(2011) C. A. Hudis et al.   ONCOLOGIST

Androgens and breast cancer

(2011) Joanne Kotsopoulos et al.   STEROIDS

Intratumoral Expression Level of Epidermal Growth Factor Receptor and Cytokeratin 5/6 Is Significantly Associated With Nodal and Distant Metastases in Patients With Basal-like Triple-Negative Breast Carcinoma

(2010) Lisa M. Sutton et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The androgen receptor in breast cancer: learning from the past

(2010) Michaela J. Higgins et al.   BREAST CANCER RESEARCH AND TREATMENT

Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features

(2010) Gulnur Guler et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer

(2010) Ayca Gucalp et al.   CANCER JOURNAL

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of androgen receptors in primary breast cancer

(2009) S. Park et al.   ANNALS OF ONCOLOGY

Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer

(2009) Gulnur Guler et al.   CANCER

Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer

(2009) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

(2009) Leo A Niemeier et al.   MODERN PATHOLOGY

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory

(2008) Zeina Nahleh   Future Oncology